Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

MLAB Mesa Laboratories Inc

Price (delayed)

$100.93

Market cap

$550.62M

P/E Ratio

N/A

Dividend/share

$0.64

EPS

-$0.36

Enterprise value

$701.25M

Mesa Labs is a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, medical device, industrial safety, environmental, and food and beverage industries. ...

Highlights
The company's EPS has surged by 99% YoY and by 99% QoQ
Mesa Laboratories's net income has surged by 99% YoY and by 99% QoQ
The company's quick ratio has shrunk by 72% YoY and by 7% QoQ

Key stats

What are the main financial stats of MLAB
Market
Shares outstanding
5.46M
Market cap
$550.62M
Enterprise value
$701.25M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.43
Price to sales (P/S)
2.27
EV/EBIT
39.35
EV/EBITDA
16.56
EV/Sales
2.91
Earnings
Revenue
$240.98M
Gross profit
$150.87M
Operating income
$16.34M
Net income
-$1.97M
EBIT
$17.82M
EBITDA
$42.35M
Free cash flow
$42.56M
Per share
EPS
-$0.36
EPS diluted
-$0.36
Free cash flow per share
$7.85
Book value per share
$29.42
Revenue per share
$44.45
TBVPS
$28.54
Balance sheet
Total assets
$433.35M
Total liabilities
$273.52M
Debt
$177.95M
Equity
$159.83M
Working capital
-$61.28M
Liquidity
Debt to equity
1.11
Current ratio
0.63
Quick ratio
0.42
Net debt/EBITDA
3.56
Margins
EBITDA margin
17.6%
Gross margin
62.6%
Net margin
-0.8%
Operating margin
6.8%
Efficiency
Return on assets
-0.4%
Return on equity
-1.3%
Return on invested capital
9.1%
Return on capital employed
6.6%
Return on sales
7.4%
Dividend
Dividend yield
0.63%
DPS
$0.64
Payout ratio
N/A

MLAB stock price

How has the Mesa Laboratories stock price performed over time
Intraday
0.81%
1 week
-2.08%
1 month
-15.23%
1 year
6.53%
YTD
-23.46%
QTD
-14.94%

Financial performance

How have Mesa Laboratories's revenue and profit performed over time
Revenue
$240.98M
Gross profit
$150.87M
Operating income
$16.34M
Net income
-$1.97M
Gross margin
62.6%
Net margin
-0.8%
MLAB's operating income has soared by 106% from the previous quarter and by 106% YoY
The operating margin has soared by 106% from the previous quarter and by 105% YoY
The net margin has soared by 99% YoY and by 99% from the previous quarter
Mesa Laboratories's net income has surged by 99% YoY and by 99% QoQ

Price vs fundamentals

How does MLAB's price correlate with its fundamentals

Growth

What is Mesa Laboratories's growth rate over time

Valuation

What is Mesa Laboratories stock price valuation
P/E
N/A
P/B
3.43
P/S
2.27
EV/EBIT
39.35
EV/EBITDA
16.56
EV/Sales
2.91
The company's EPS has surged by 99% YoY and by 99% QoQ
MLAB's price to book (P/B) is 14% less than its last 4 quarters average of 4.0 but 11% more than its 5-year quarterly average of 3.1
MLAB's equity is up by 10% year-on-year and by 3% since the previous quarter
The P/S is 61% below the 5-year quarterly average of 5.8 and 16% below the last 4 quarters average of 2.7
MLAB's revenue is up by 11% year-on-year

Efficiency

How efficient is Mesa Laboratories business performance
Mesa Laboratories's return on invested capital has surged by 110% YoY and by 108% QoQ
The company's return on sales has surged by 107% QoQ and by 106% YoY
The return on assets has surged by 99% since the previous quarter and by 99% year-on-year
MLAB's return on equity has surged by 99% since the previous quarter and by 98% year-on-year

Dividends

What is MLAB's dividend history
DPS
$0.64
Dividend yield
0.63%
Payout ratio
N/A
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Mesa Laboratories financials performed over time
Mesa Laboratories's total assets is 58% more than its total liabilities
MLAB's current ratio has dropped by 74% year-on-year and by 11% since the previous quarter
The company's quick ratio has shrunk by 72% YoY and by 7% QoQ
The debt is 11% more than the equity
MLAB's debt to equity is down by 27% YoY and by 12% QoQ
The debt has contracted by 20% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.